The Blue Cross Blue Shield Association has announced a partnership with a Google-affiliated company to provide personalized type 2 diabetes care to members of its health plans. READ MORE
The Blue Cross Blue Shield Association has announced a partnership with a Google-affiliated company to provide personalized type 2 diabetes care to members of its health plans.
Heart failure patients may be less likely to be hospitalized or die prematurely if they don’t also have diabetes – but even if they do have it, they may still minimize their risk by controlling their blood sugar.
A recent analysis of real-world data has shown that switching insulin therapies is highly cost-effective for the treatment of type 1 and type 2 diabetes.
A real-life analysis compared multiple antidiabetic medications for increased risk of heart failure hospitalization.
Research in Review
A biomarker screening pathway for monogenic diabetes is an effective and easy approach to systematically screening young-onset patients.
Continuous subcutaneous insulin infusion is associated with increased hypoglycemia encounters and health care expenditures.
Researchers compared angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers for protecting type 2 diabetes patients.
Bariatric surgery is more effective than standard medical treatment for the long-term control of type 2 diabetes in obese patients.
According to a recent clinical practice guideline, the management of type 2 diabetes should include shared decision-making, individualized diabetes self-management education, and individualized glycemic management plans.